Novel Catalyst Systems

Information

  • Research Project
  • 8196637
  • ApplicationId
    8196637
  • Core Project Number
    R43GM088939
  • Full Project Number
    1R43GM088939-01A2
  • Serial Number
    88939
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    9/1/2011 - 14 years ago
  • Project End Date
    8/31/2013 - 12 years ago
  • Program Officer Name
    FABIAN, MILES
  • Budget Start Date
    9/1/2011 - 14 years ago
  • Budget End Date
    8/31/2013 - 12 years ago
  • Fiscal Year
    2011
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    8/25/2011 - 14 years ago

Novel Catalyst Systems

DESCRIPTION (provided by applicant): Transition metal catalysts are widely used in the pharmaceutical industry for the production of active ingredients, precursors and new drug candidates. These products must be very pure, often requiring labor and energy intensive separation processes, to achieve the required purity levels. Of special concern in the present context is to avoid contaminating the product with the transition metal catalyst used during its synthesis. The above references are far from an exhaustive list but suggest the breadth and importance of the chemistry available from palladium catalysts. Palladium catalyzed reactions are ubiquitous in pharmaceutical process chemistry. Many synthetic processes rely on both heterogeneous and homogeneous catalysis. However, Pd is highly toxic, and the allowable level of palladium in an active pharmaceutical ingredient (API) is highly regulated, and must be less than 5 ppm (oral) or 0.5 ppm (parenteral). Accordingly, there is considerable interest in the development of new technologies that will ameliorate the problem of metal contamination in Pd- catalyzed processes. A variety of scavenger and filtering methods are used for removing palladium from APIs. Palladium removal essentially adds an extra step to a synthesis, and is consequently costly in terms of time and money. Although palladium catalysis is the major focus of this proposal, other metal species are also of interest. Compact Membrane Systems, Inc. (CMS) proposes a new catalyst system that provides the needed catalytic reactivity as described above but eliminates the extra steps associated with reducing/eliminating contamination. In Phase I CMS will fabricate palladium system, demonstrate its catalytic capability and determine contamination level in produce. Contingencies are included and overall economic evaluation is included. PUBLIC HEALTH RELEVANCE: It is proposed to eliminate the problem of leaching of transition metal catalysts into pharmaceutical process streams, which can contaminate the product and result in loss of costly catalyst materials. Combining fluorous technology with membranes we further enhance the ability to separate metal and other components from organic species. Successful implementation of this technology should result in higher purity, lower cost products.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    167022
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:167022\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    COMPACT MEMBRANE SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    808898894
  • Organization City
    NEWPORT
  • Organization State
    DE
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    198042410
  • Organization District
    UNITED STATES